Obesity and prostate enlargement in men with localized prostate cancer

BJU International

Volumn 108, Issue 11, 2011, Pages 1750-1755

  Kopp, Ryan P ^a   Han, Misop ^b   Partin, Alan W ^b   Humphreys, Elizabeth ^b   Freedland, Stephen J ^c,d   Parsons, J Kellogg ^a,e,f  

^a UCSD MEDICAL CENTER   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

benign prostatic hyperplasia; body mass index; obesity; prostate; prostate cancer; radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; ORGAN WEIGHT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE WEIGHT; PROSTATECTOMY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

AGED; BODY MASS INDEX; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; ORGAN SIZE; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 81255137023     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10227.x     Document Type: Article

References (52)

1. Flegal KM, Carroll MD, Ogden CL, Curtin LR,. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303: 235-41
2. Jayachandran J, Banez LL, Aronson WJ, et al,. Obesity as a predictor of adverse outcome across black and white race: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 2009; 115: 5263-71
3. Freedland SJ, Banez LL, Sun LL, Fitzsimons NJ, Moul JW,. Obese men have higher-grade and larger tumors: an analysis of the Duke Prostate Center Database. Prostate Cancer Prostatic Dis 2009; 12: 259-63
4. Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D,. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998; 1: 157-62 (Pubitemid 128545860)
5. Parsons JK, Carter HB, Partin AW, et al,. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006; 91: 2562-8 (Pubitemid 44024618)
6. Parsons JK, Sarma AV, McVary K, Wei JT,. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J Urol 2009; 182: S27-31
7. Freedland SJ, Platz EA, Presti JC Jr, et al. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol 2006; 175: 500-4; discussion 504 (Pubitemid 43067337)
8. Parekh N, Lin Y, Dipaola RS, Marcella S, Lu-Yao G,. Obesity and prostate cancer detection: insights from three national surveys. Am J Med 2010; 123: 829-35
9. Sajadi KP, Terris MK, Hamilton RJ, et al. Body mass index, prostate weight and transrectal ultrasound prostate volume accuracy. J Urol 2007; 178: 990-5 (Pubitemid 47211082)
10. Jeong CW, Park HK, Hong SK, Byun SS, Lee HJ, Lee SE,. Comparison of prostate volume measured by transrectal ultrasonography and MRI with the actual prostate volume measured after radical prostatectomy. Urol Int 2008; 81: 179-85
11. Andriole GL, Bostwick DG, Brawley OW, et al,. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192-202
12. Cohen YC, Liu KS, Heyden NL, et al,. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007; 99: 1366-74 (Pubitemid 351767189)
13. Finne P, Finne R, Auvinen A, et al,. Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. Urology 2000; 56: 418-22 (Pubitemid 30658171)
14. Kranse R, Beemsterboer P, Rietbergen J, Habbema D, Hugosson J, Schroder FH,. Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region). Prostate 1999; 39: 316-22 (Pubitemid 29244508)
15. Bova GS, Fox WM, Epstein JI,. Methods of radical prostatectomy specimen processing: a novel technique for harvesting fresh prostate cancer tissue and review of processing techniques. Mod Pathol 1993; 6: 201-7
16. Lee S, Min HG, Choi SH, et al,. Central obesity as a risk factor for prostatic hyperplasia. Obesity (Silver Spring) 2006; 14: 172-9 (Pubitemid 46214787)
17. Soygur T, Kupeli B, Aydos K, Kupeli S, Arikan N, Muftuoglu YZ,. Effect of obesity on prostatic hyperplasia: its relation to sex steroid levels. Int Urol Nephrol 1996; 28: 55-9 (Pubitemid 26172023)
18. Joseph MA, Wei JT, Harlow SD, et al,. Relationship of serum sex-steroid hormones and prostate volume in African American men. Prostate 2002; 53: 322-9 (Pubitemid 35398502)
19. Sarma AV, Jaffe CA, Schottenfeld D, et al,. Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and body mass index: clinical correlates of prostate volume among Black men. Urology 2002; 59: 362-7 (Pubitemid 34189735)
20. Baillargeon J, Pollock BH, Kristal AR, et al,. The association of body mass index and prostate-specific antigen in a population-based study. Cancer 2005; 103: 1092-5 (Pubitemid 40270087)
21. Gray MA, Delahunt B, Fowles JR, Weinstein P, Cookes RR, Nacey JN,. Demographic and clinical factors as determinants of serum levels of prostate specific antigen and its derivatives. Anticancer Res 2004; 24: 2069-72 (Pubitemid 38954635)
22. Ku JH, Kim ME, Lee NK, Park YH, Ahn JO,. Influence of age, anthropometry, and hepatic and renal function on serum prostate-specific antigen levels in healthy middle-age men. Urology 2003; 61: 132-6 (Pubitemid 36151728)
23. Cohen PG,. The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt-a major factor in the genesis of morbid obesity. Med Hypotheses 1999; 52: 49-51
24. Banez LL, Hamilton RJ, Partin AW, et al,. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007; 298: 2275-80 (Pubitemid 350146217)
25. Parsons JK,. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol 2007; 178: 395-401 (Pubitemid 47030484)
26. Furukawa S, Fujita T, Shimabukuro M, et al,. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752-61 (Pubitemid 40385531)
27. Haffner SM,. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 2006; 97: 3A-11A (Pubitemid 43139714)
28. Anim JT, Udo C, John B,. Characterisation of inflammatory cells in benign prostatic hyperplasia. Acta Histochem 1998; 100: 439-49 (Pubitemid 28524620)
29. Nickel JC, Downey J, Young I, Boag S,. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 1999; 84: 976-81
30. Theyer G, Kramer G, Assmann I, et al,. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest 1992; 66: 96-107
31. Di Silverio F, Gentile V, De Matteis A, et al,. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol 2003; 43: 164-75 (Pubitemid 36221971)
32. Steiner GE, Newman ME, Paikl D, et al,. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 2003; 56: 171-82 (Pubitemid 36918167)
33. Steiner GE, Stix U, Handisurya A, et al,. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest 2003; 83: 1131-46 (Pubitemid 37013048)
34. Kramer G, Mitteregger D, Marberger M,. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 2007; 51: 1202-16 (Pubitemid 46436310)
35. Rohrmann S, De Marzo AM, Smit E, Giovannucci E, Platz EA,. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate 2005; 62: 27-33 (Pubitemid 39614290)
36. St Sauver JL, Jacobson DJ, McGree ME, Lieber MM, Jacobsen SJ,. Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol 2006; 164: 760-8 (Pubitemid 44522080)
37. Quintar AA, Doll A, Leimgruber C, et al,. Acute inflammation promotes early cellular stimulation of the epithelial and stromal compartments of the rat prostate. Prostate 2010; 70: 1153-65
38. Partin AW, Oesterling JE, Epstein JI, Horton R, Walsh PC,. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol 1991; 145: 405-9
39. Becker S, Dossus L, Kaaks R,. Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch Physiol Biochem 2009; 115: 86-96
40. Bergman RN, Kim SP, Hsu IR, et al,. Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. Am J Med 2007; 120: S3-8; discussion S29-32 (Pubitemid 46216205)
41. Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW,. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002; 168: 599-604 (Pubitemid 34793304)
42. Hammarsten J, Hogstedt B,. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001; 39: 151-8 (Pubitemid 32171181)
43. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A,. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 2007; 51: 199-203; discussion 204-6
44. Vikram A, Jena GB, Ramarao P,. Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia. Prostate 2010; 70: 79-89
45. Vikram A, Jena G, Ramarao P,. Insulin-resistance and benign prostatic hyperplasia: the connection. Eur J Pharmacol 2010; 641: 75-81
46. Turley RS, Hamilton RJ, Terris MK, et al,. Small transrectal ultrasound volume predicts clinically significant Gleason score upgrading after radical prostatectomy: results from the SEARCH database. J Urol 2008; 179: 523-7; 52discussion 7-8
47. Turley RS, Terris MK, Kane CJ, et al,. The association between prostate size and Gleason score upgrading depends on the number of biopsy cores obtained: results from the Shared Equal Access Regional Cancer Hospital Database. BJU Int 2008; 102: 1074-9
48. Briganti A, Chun FK, Suardi N, et al,. Prostate volume and adverse prostate cancer features: fact not artifact. Eur J Cancer 2007; 43: 2669-77 (Pubitemid 350151846)
49. Hammarsten J, Hogstedt B,. Calculated fast-growing benign prostatic hyperplasia-a risk factor for developing clinical prostate cancer. Scand J Urol Nephrol 2002; 36: 330-8 (Pubitemid 35373619)
50. Hammarsten J, Hogstedt B,. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 2005; 41: 2887-95 (Pubitemid 41713128)
51. Alcaraz A, Hammerer P, Tubaro A, Schroder FH, Castro R,. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol 2009; 55: 864-73
52. Salomon L, Levrel O, Anastasiadis AG, et al,. Prognostic significance of tumor volume after radical prostatectomy: a multivariate analysis of pathological prognostic factors. Eur Urol 2003; 43: 39-44 (Pubitemid 36134314)